Japanese Scientists Turn Cancer Cells Against Themselves in New Experiments

Japanese Scientists Develop a New Strategy to Target Cancer Cells

Researchers in Japan have demonstrated a promising experimental approach that uses a tumour’s own chemistry to activate anticancer compounds from within cancer cells.

The research, led by Katsunori Tanaka and his team at the RIKEN Pioneering Research Institute, explores how carbon monoxide produced in certain cancer cells can be used as a chemical trigger to synthesise a toxic compound inside them.

Published in Nature Communications, the study represents an early proof of concept for a strategy that could eventually help researchers target cancer cells more selectively while reducing damage to healthy tissue.

How Does the Cancer Cell Self-Destruction Technique Work?

The method takes advantage of a chemical difference that researchers observed between the cancer cell lines they tested and a non-cancerous cell line.

The team designed a system involving a palladium-based catalyst carried within albumin, a protein naturally found in blood. Once the catalyst enters a cell, it can use available carbon monoxide to trigger a chemical reaction that produces phenanthridinone derivatives, compounds that include substances with cell-killing properties.

In the experiments, the researchers detected the intended chemical product in several cancer cell lines, including liver, cervical, breast and lung cancer cells, but not in the non-cancerous cell line they tested.

The researchers then adjusted the system to produce a toxic compound inside liver cancer cells and observed the expected harmful effects on those cells.

Why Using Cancer Cells’ Own Chemistry Matters

One of the biggest challenges in cancer treatment is destroying malignant cells without causing excessive damage to healthy tissue.

Conventional chemotherapy can affect healthy, rapidly dividing cells as well as cancer cells, contributing to side effects. Researchers are therefore exploring approaches that activate drugs specifically at tumour sites rather than exposing the entire body to an active anticancer compound.

The Japanese team’s approach attempts to make the cancer cell’s internal environment part of the treatment mechanism. Instead of simply delivering a fully active drug, the system aims to generate a toxic compound where the chemical conditions allow the reaction to occur.

If the approach can eventually be made sufficiently selective in living organisms, it could offer a new direction for targeted drug delivery. However, the laboratory results do not yet establish that healthy tissues would be protected in a human patient.

A Promising Experiment, Not Yet a Cancer Cure

Despite the encouraging results, the technique remains at an early research stage.

The experiments were conducted using cultured cells. The researchers identified moving from cell cultures to animal models as the next step in evaluating the approach.

Before it could become a treatment, scientists would need to determine whether the catalyst reaches tumours reliably, whether enough of the active compound is produced, how long it remains in the body and whether it causes harmful effects in healthy tissues.

Researchers would also need to establish whether the technique works across different tumour types and whether cancer cells could evade its effects.

These questions matter because results in isolated cells do not necessarily translate into effective or safe treatments in humans.

Another Japanese Breakthrough Uses Programmed Cell Death

A separate Japanese research project has also explored ways to trigger cells to self-destruct, although it has a different purpose.

In September 2026, researchers from RIKEN, Japan’s National Institute of Advanced Industrial Science and Technology, and Kyushu University announced the development of AuxiCasp9, a molecular safety switch designed to trigger programmed cell death in genetically engineered therapeutic cells.

The system activates caspase 9 using a derivative of the plant hormone auxin. Its intended role is to help shut down engineered cells if they cause adverse effects during cell therapy, rather than directly treating cancer cells.

The distinction is important: this technology could improve the safety of certain cell-based treatments, while the carbon-monoxide-triggered method aims to generate anticancer compounds inside cancer cells. Both demonstrate how scientists are exploring precise control over cellular processes, but they address different medical challenges.

What This Could Mean for the Future of Cancer Treatment

The broader goal behind this research is to make cancer therapies more selective, reducing the collateral damage that can accompany treatment.

By using chemical signals associated with tumour cells to activate therapeutic compounds, researchers hope to develop systems that work more directly at the disease site. Similar strategies could eventually complement existing treatments if they prove effective and safe in further studies.

For now, the Japanese team’s findings are best understood as an early experimental advance, not evidence that cancer can already be cured by making tumour cells destroy themselves.

The next major milestone will be demonstrating that the technique works safely and effectively in animal models before researchers can assess its potential for clinical development.